Neuropharmacological relation of religious belief supports the role of dopaminergic activation
as the leading neurochemical feature. However, vesicular monoamine transporter-2 (VMAT-2) has been
shown to be responsible for removing of neurotransmitters such as dopamine that may secondarily lead to
a neuroprotective activity by different neurodegeneration models. Moreover, there are interesting data
showing that VMAT-2 may play an important role during religious belief and experience. In the light of these findings,
we aimed to review the preclinical and clinical neuroprotective data of Vesicular monoamine transporter (VMAT-2) in
different neurodegenerative and neuropsychiatric diseases. In respect of rapidly increasing evidences about the neurobiological
and neuroimaging correlates of religious belief, we hypothesized that there is a link between belief and neuroprotection.